

# Haiyan Jiang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5161565/publications.pdf>

Version: 2024-02-01

32  
papers

5,985  
citations

257357

24  
h-index

434063

31  
g-index

32  
all docs

32  
docs citations

32  
times ranked

3756  
citing authors

#	ARTICLE	IF	CITATIONS
1	BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. <i>Blood</i> , 2020, 135, 1484-1496.	0.6	59
2	Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. <i>Blood</i> , 2016, 128, 104-109.	0.6	81
3	Recombinant factor VIII Fc (rFVIII Fc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. <i>Cellular Immunology</i> , 2016, 301, 30-39.	1.4	53
4	Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice. <i>PLoS ONE</i> , 2016, 11, e0148255.	1.1	2
5	FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes. <i>PLoS ONE</i> , 2015, 10, e0124930.	1.1	19
6	Population pharmacokinetics of recombinant factor VIII Fc fusion protein. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 163-174.	0.8	42
7	Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion. <i>Thrombosis Research</i> , 2015, 135, 970-976.	0.8	15
8	Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals. <i>Thrombosis Research</i> , 2015, 136, 371-378.	0.8	6
9	Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals. <i>Thrombosis Research</i> , 2015, 136, 1266-1272.	0.8	3
10	Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. <i>Critical Reviews in Biotechnology</i> , 2015, 35, 235-254.	5.1	201
11	A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity. <i>PLoS ONE</i> , 2014, 9, e113600.	1.1	12
12	Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B. <i>Clinical Pharmacokinetics</i> , 2014, 53, 467-477.	1.6	40
13	Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. <i>Blood</i> , 2014, 123, 317-325.	0.6	403
14	Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. <i>New England Journal of Medicine</i> , 2013, 369, 2313-2323.	13.9	307
15	Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. <i>Blood</i> , 2012, 119, 666-672.	0.6	167
16	Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. <i>Blood</i> , 2012, 119, 3031-3037.	0.6	215
17	Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. <i>Blood</i> , 2012, 119, 3024-3030.	0.6	139
18	Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. <i>Blood</i> , 2010, 115, 4678-4688.	0.6	104

#	ARTICLE	IF	CITATIONS
19	Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. <i>Blood</i> , 2010, 116, 270-279.	0.6	225
20	Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. <i>Blood</i> , 2009, 114, 2802-2811.	0.6	39
21	Site-Specific PEGylation of Factor VIII (PEG-FVIII) Preserves Full Clotting Activity and Extends Therapeutic Efficacy in HemophiliaA Dogs. <i>Blood</i> , 2008, 112, 511-511.	0.6	18
22	The Enhancing Effects of the Light Chain on Heavy Chain Secretion in Split Delivery of Factor VIII Gene. <i>Molecular Therapy</i> , 2007, 15, 1856-1862.	3.7	39
23	Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. <i>Blood</i> , 2007, 110, 2334-2341.	0.6	218
24	CD8+ T-cell responses to adeno-associated virus capsid in humans. <i>Nature Medicine</i> , 2007, 13, 419-422.	15.2	629
25	Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene Transfer to Skeletal Muscle in an Individual with Severe Hemophilia B. <i>Molecular Therapy</i> , 2006, 14, 452-455.	3.7	196
26	Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. <i>Blood</i> , 2006, 107, 1810-1817.	0.6	236
27	Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. <i>Blood</i> , 2006, 108, 107-115.	0.6	189
28	Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. <i>Blood</i> , 2006, 108, 3321-3328.	0.6	295
29	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. <i>Nature Medicine</i> , 2006, 12, 342-347.	15.2	1,865
30	An Essential Role of the Factor VIII Light Chain in Facilitating Heavy Chain Secretion.. <i>Blood</i> , 2006, 108, 4034-4034.	0.6	0
31	Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. <i>Blood</i> , 2003, 102, 3919-3926.	0.6	67
32	Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. <i>Blood</i> , 2003, 102, 2031-2037.	0.6	101